it is an acute cervical spinal cord injury and is marked by a disproportionately greater impairment of motor function in the upper extremities than in the lower ones.
Highly malignant tumor of mesenchymal origin.Spindle shaped cells that produce osteoid.2nd most common primary malignant bone tumor after MM.Incidence – 1 to 3 per million per year
Treated by chemo,amputation or rotationplasty
1.Anatomy
a.Course
b.Motor distribution
c.Sensory distribution
2.Common sites affected
3.Level of median nerve injury
4.Clinical feature with various test performed
5.Various syndromes related to median nerve
6.Treatment
7.Summary
it is an acute cervical spinal cord injury and is marked by a disproportionately greater impairment of motor function in the upper extremities than in the lower ones.
Highly malignant tumor of mesenchymal origin.Spindle shaped cells that produce osteoid.2nd most common primary malignant bone tumor after MM.Incidence – 1 to 3 per million per year
Treated by chemo,amputation or rotationplasty
1.Anatomy
a.Course
b.Motor distribution
c.Sensory distribution
2.Common sites affected
3.Level of median nerve injury
4.Clinical feature with various test performed
5.Various syndromes related to median nerve
6.Treatment
7.Summary
Diabetic polyneuropathy
Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.
Identified in 1921 by James Ewing
2nd most common bone tumor in children
Ewing’s Sarcoma Family of tumors:
Ewing’s sarcoma (Bone –87%)
Extraosseous Ewing’s sarcoma (8%)
Peripheral PNET(5%)
Askin’s tumor
Diabetic polyneuropathy
Diabetic polyneuropathy (DPN) is defined as peripheral nerve dysfunction. There are three main alterations involved in the pathologic changes of DPN: inflammation, oxidative stress, and mitochondrial dysfunction.
Identified in 1921 by James Ewing
2nd most common bone tumor in children
Ewing’s Sarcoma Family of tumors:
Ewing’s sarcoma (Bone –87%)
Extraosseous Ewing’s sarcoma (8%)
Peripheral PNET(5%)
Askin’s tumor
This presentation is a comprehensive & updated presentation that delves deeply into Multiple Sclerosis. It is intended for healthcare professionals and features the Anatomy and Physiology, Common Etiology, a focused review of the disease Pathophysiology, Prevalence & Morbidity, Clinical Manifestations, Diagnostics, Classification & Prognosis, Treatment (Both current and experimental), Nutrition, and Psychosocial issues and resources available to patients. It is very rich in details, diagrams (on every slide), and interactive content when in slide presentation mode. The presentation has also hyperlinks to videos (3 D Patho) and controversial treatments. Finally, it concludes with a Case Study to highlight the clinical application.
Please note that you're welcome to use any slides as long as you reference my post when you do so to maintain the integrity of authorship
If interested in detailed answers, please email: aamirdash@yahoo.com
Thanks, Ahmad
A wonderful and interesting presentation on Multiple Sclerosis! It includes videos, pictures and great insight into the possible cure for MS. I truly hope whoever downloads it enjoys it as much as I do. Blessings!
Creando el mapa de la susceptibilidad genética y un modelo de patogénesis en ...Fundación Ramón Areces
Ciclo de conferencias y debates en Ciencias.
Fundación Ramón Areces-Nature Publishing Group.
Jorge R. Oksenberg. Universidad de California, San Francisco, EE. UU.
Madrid, 2 de febrero de 2012
Epstein-Barr virus genetic variants are associated with multiple sclerosis.Mutiple Sclerosis
Rosella Mechelli, Caterina Manzari, Claudia Policano, Anita Annese, Ernesto Picardi, Renato Umeton, Arianna Fornasiero, Anna Maria D’Erchia, Maria Chiara Buscarinu, Cristina Agliardi, Viviana Annibali, Barbara Serafini, Barbara Rosicarelli, Silvia Romano, Daniela F. Angelini, Vito A.G. Ricigliano, Fabio Buttari, Luca Battistini, Diego Centonze, Franca R. Guerini, Sandra D’Alfonso, Graziano Pesole, Marco Salvetti, Giovanni Ristori
OBJECTIVE:
We analyzed the Epstein-Barr nuclear antigen 2 (EBNA2) gene, which contains the most variable region of the viral genome, in persons with multiple sclerosis (MS) and control subjects to verify whether virus genetic variants are involved in disease development.
METHODS:
A seminested PCR approach and Sanger sequencing were used to analyze EBNA2 in 53 patients and 38 matched healthy donors (HDs). High-throughput sequencing by Illumina MiSeq was also applied in a subgroup of donors (17 patients and 17 HDs). Patients underwent gadolinium-enhanced MRI and human leucocyte antigen typing.
RESULTS:
MS risk significantly correlated with an excess of 1.2 allele (odds ratio [OR] = 5.13; 95% confidence interval [CI] 1.84-14.32; p = 0.016) and underrepresentation of 1.3B allele (OR = 0.23; 95% CI 0.08-0.51; p = 0.0006). We identified new genetic variants, mostly 1.2 allele- and MS-associated (especially amino acid variation at position 245; OR = 9.4; 95% CI 1.19-78.72; p = 0.0123). In all cases, the consensus sequence from deep sequencing confirmed Sanger sequencing (including the cosegregation of newly identified variants with known EBNA2 alleles) and showed that the extent of genotype intraindividual variability was higher than expected: rare EBNA2 variants were detected in all HDs and patients with MS (range 1-17 and 3-19, respectively). EBNA2 variants did not seem to correlate with human leucocyte antigen typing or clinical/MRI features.
CONCLUSIONS:
Our study unveils a strong association between Epstein-Barr virus genomic variants and MS, reinforcing the idea that Epstein-Barr virus contributes to disease development.
Multiple sclerosis is generally referred to as an autoimmune disease or disorder in which the nerve cells of brain and spinal cord are attacked by patients own immune system.
The patient's bodys immune system perceives myelin sheet as an intruder and attack it resulting in damage due to which this sheet no longer carry the messages properly causing the message transmission process to be slowed, distorted or stopped altogether.
At present there is no cure available for multiple sclerosis, however, using certain drugs such as interferon’s, exercise and physiotherapy it is possible to manage the attacks and symptoms.
Researchers hope that stem cell therapies may provide new approaches that can both prevent damage and enable us to repair it.
Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body.
No one knows what causes MS. It may be an autoimmune disease, which happens when your body attacks itself. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak or walk. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help.
Effects of Antioxidants on Age and Multiple Sclerosis-Related Oxidative Stressarsosa
Abstract: Multiple sclerosis (MS) is a chronic and debilitating disease of the central nervous system (CNS). The pathogenesis of MS involves neurodegeneration which may be due to oxidative stress. Antioxidants such as vitamins have been studied as modifiers and biomarkers of oxidative stress in MS patients. MS progression, specifically that in which relapsing-remitting multiple sclerosis (RRMS) transitions to secondary-progressive multiple sclerosis (SPMS), is independent of disease onset and duration, but correlated with age. Because of the neurodegenerative effects of oxidative stress and the age-dependent course of MS, it is possible that the transition from RRMS to SPMS is caused by levels of oxidative stress that may increase with age. This study investigates the role of antioxidants α-tocopherol, glutathione, and uric acid on oxidative stress and subsequent MS progression. Further, I intend to compare the different effects of antioxidant supplements on RRMS patients, SPMS patients, and relatively healthy individuals based on cerebrospinal fluid and serum samples.
Preliminary report describing a targeted sequencing study in 1500 MS cases and 1500 controls. I presented this at the ASHG 2011 session on large scale resequencing.
Criterios diagnosticos de enfermedad de parkinson, esta version es comparada con los criterior diagnosticos del Banco de cerebros de londres, y se encuentra que es mas sensible y especifica
Fibromyalgia Over-Diagnosed 97% of the timeNelson Hendler
97% of patients told they have fibromyalgia do not meet the diagnostic criteria for this diagnosis, and have treatable disorders, such as nerve entrapments, thoracic outlet syndrome, discs which do not show on MRI, facet syndromes, etc.
Comparative Observational Studies Major types of these designs are cross-sectional studies, case-control studies, and cohort studies (both retrospective and prospective)
Using real-world evidence to investigate clinical research questionsKarin Verspoor
Adoption of electronic health records to document extensive clinical information brings with it the opportunity to utilise that information to support clinical research, and ultimately to support clinical decision making. In this talk, I discuss both these opportunities and the challenges that we face when working with real-world clinical data, and introduce some of the strategies that we are adopting to make this data more usable, and to extract more value from it. I specifically discuss the use of natural language processing to transform clinical documentation into structured data for this purpose.
What is research, Types of research, Requisites of good research, Concept in epidemiology, Epidemiologic studies , Literature search, Protocol designing, Ethical issues, Dissertation writing , Research paper writing , Reviewing a research paper
Comparisonof Clinical Diagnoses versus Computerized Test Diagnoses Using the ...Nelson Hendler
The Diagnostic Paradigm from www.MarylandClinicalDiagnostics.com was able to help the former Dean of Los Angeles Chiropractic College detect medical diagnoses which he had overlooked, and he later confirmed.
Study of the distribution and determinants of
health-related states or events in specified populations and the application of this study to control health problems.
John M. Last, Dictionary of Epidemiology
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
2. introduction
• Diagnosis of multiple sclerosis (MS) requires
exclusion of diseases that could better explain
the clinical and paraclinical findings.
• A systematic process for exclusion of alternative
diagnoses has not been defined.
• An International Panel of MS experts developed
consensus perspectives on MS differential
diagnosis using available literature and
consensus.
3. Methods
• International Task Force composition and
mission
• International Advisory Committee on Clinical
Trials in MS of the US National MS Society use
to address the principle of “no better
explanation”for a suspected MS clinical
presentation.
• 18 international (UnitedStates, Canada, Europe,
Japan) experts in the field of demyelinating
disease with differing clinical and research
expertise in(neurology,ophthalmology,infectious
disease, MRI)
4. objectives
• recommendations for
1) clinical and paraclinical red flags suggesting alternative
diagnoses to MS;
2) more precise definition of “clinically isolated
syndromes” (CIS), often the first presentations of MS or
its alternatives;
3) algorithms for diagnosis of three common CISs
related to MS in the optic nerves, brainstem, and spinal
cord; and
4) a classification scheme and diagnosis criteria for
idiopathic inflammatory demyelinating disorders of the
central nervous system.
5. Task Force work plan
• three working groups
• Series of conference calls and subgroup
meetings over a year and a meeting of the
full Task Force in February2007.
• Opinion-based consensus
6. • Diagnostic evaluation strategies apply to individuals with:
• 1) Clinical, laboratory, and imaging features that are “classic”
for MS and where no features strongly suggest an alternative
diagnosis. MS is likely. Additional examinations or tests beyond
those that satisfy the McDonald criteria for MS are likely
unnecessary.
2) Features that are compatible with MS but occur in the
presence of other features (red flags) that suggest a possible
alternative diagnosis. MS can
only be diagnosed after tests to exclude alternative diagnoses.
In equivocal situations, repeated imaging and laboratory tests
over a period ofobservation may be advisable before reaching a
conclusive diagnosis.
3) Clinical and/or paraclinical red flags that point to a non-MS
diagnosis. MS is improbable. Efforts should be directed at
defining the alternative condition, especially when treatable.
4) Clinical and/or paraclinical findings that suggest the presence
of MS with another superimposed disorder. Appropriate
imaging and laboratory tests should be performed to confirm
the coexistence of the two conditions.
7. Exclusion of diagnostic alternatives
• One subgroup reviewed selected literature relating to demographics
, general clinical and neurological findings, paraclinical and
laboratory findings (including various imaging techniques and
laboratory tests including serum and cerebrospinal fluid [CSF]
analyses and evoked potentials) of a spectrum of diseases that
might be reasonably considered in the differential diagnoses for MS.
• a table of 79 demographic, clinical, laboratory, and imaging features
was prepared. The table was rated independently by the six
subgroup members on a 1–5 scale to classify these characteristics
as major red flags (rating 4 or 5) that point fairly definitively to a
specific non-MS alternative diagnosis or as minor red flags (rating 1
or 2), which suggest that a disorder other than MS should be
considered. An intermediate score (rating 3) indicated
uncertainty.Scores on each finding from each rater were summed
and standard deviations (SD) were calculated for each item (a high
SD represents a low degree of concordance among raters).
• .
8. • Potential 79 red flags were then classified into three
groups according to the following criteria:
• Major red flags: total score ≥24 or total score of
23 and no more than one individual score of 3(SD ≤
0.41).
• Intermediate red flags, indicating a lack of agreement
among the raters about the weighting:total score of ≥13
and ≤23 with more than one individual rating of 3 (SD ≥
4.1).
• Minor red flags: total score ≤12 or total score of 13 with
not more than one individual score of 3(SD ≤ 0.41).
9. • 36 major red flags were identified that point fairly
definitively to a non-MS alternative diagnosis, the
majority of which are clinical in nature.
• Eleven minor red flags were identified that suggest while
MS is a possible diagnosis, a disorder other than MS
should be considered, and that a decision cannot be
made simply based on the noted assessment alone.
• An additional 32 clinical, paraclinical, and laboratory
assays, many of which are imaging findings, were
determined to be of intermediate weight
10.
11.
12.
13.
14.
15.
16. Diagnostic algorithms for common
initial isolated
syndromes suggestive of MS
• A second subgroup focused on CISs that
are frequently seen as a first presentation
of disease that is eventually diagnosed as
MS
• the subgroup developed diagnostic
algorithms for three of the most typical
CISs (optic neuropathy,brain stem, and
spinal cord syndromes
17. Defining and classifying CIS
• CIS should be defined as a monophasic
presentation with suspected underlying
inflammatory demyelinating disease.
• “Monophasic presentation” implies a single
clinical episode at first presentation that is of
relatively rapid onset. Multiple simultaneous
clinical/ paraclinical presentations (representing
dissemination in space) are possible, although
dissemination in time should not be evident.
Four classes of CIS can thus be defined .
18.
19.
20.
21.
22.
23. Differentiating MS from non-MS
IIDDs
• A third subgroup evaluated clinical,
demographic, and paraclinical factors that
differentiate prototypic MS from “variants,”
such as NMO and ADEM, and proposed
consensus criteria for their diagnosis in
light of recent data on specific imaging
features and biomarkers.
24.
25.
26.
27. conclusions
• range of diseases that must be excluded to make a diagnosis of MS
is wide.
• conclusions and recommendations are largely consensus driven
and should be assessed in prospective clinical studies.
• Each red flag was rated by the Panel in isolation and not in a larger
clinical and/paraclinical context.
• Defining sets of symptoms/signs and red flags that would increase
the diagnostic confidence in making a diagnosis of MS versus other
conditions is a high research priority.
• relative prevalence of disorders in a specific geographic area or
population should be considered in reaching a diagnosis.
• Regional ethnically based differences in disease definition.
• Disease biomarkers will aid enormously in differential diagnosis.